Growing Adoption of Single Nucleotide Polymorphism (SNP) Chips to Offer Opportunities for Direct-to-Consumer Genetic Testing Market
According to our new research study on "Direct-to-Consumer Genetic Testing Market Forecast to 2030 – Global Analysis – by Test Type, Technology, Distribution Channel, and Geography," the market size was valued at US$ 1,715.84 million in 2022 and is expected to reach US$ 7,191.68 million by 2030. It is estimated to register a CAGR of 19.6% from 2022 to 2030.
There has been a steady paradigm shift from traditional medicine to personalized medicine with increasing scientific knowledge in recent years. This shift is due to advances in genetic engineering, single nucleotide polymorphism (SNP) genotyping, and the high adoption of microarrays and biochip technologies. The introduction of genetic microarray analysis platforms with hundreds of thousands of SNPs will encourage the implementation of advanced algorithms to test for more secluded genealogical relationships more openly between individuals. In addition, the demand for detecting malignant tumors has also increased. In the pediatric field, the short turnaround time without the need to hybridize SNP variations to massive deletions has led to enormous demand for genetic testing. As a result, the market is expected to grow as more genetic abnormalities are detected and treated.
Direct-to-Consumer Genetic Testing Market Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Test Type (Nutrigenomics Testing, Predictive Testing, Carrier Testing, and Others), Technology (Whole Genome Sequencing, Single Nucleotide Polymorphism Chips, Targeted Analysis, and Others), Distribution Channel (Online and Offline), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Direct-to-Consumer Genetic Testing Market Report | Size & Share 2030
Download Free Sample
SNP chips with high efficiency and accuracy are witnessing an increase in demand due to the constant need for technologically advanced and more sophisticated DTC genetic testing. A high preference for SNP chips can be attributed to their ability to measure dosage changes and DNA polymorphism, along with various applications such as the SNP microarray analysis that are vital for cancer research. Furthermore, an increasing need to minimize errors in DTC genetic testing is expected to drive the adoption of SNP technology, thereby providing an opportunity for the market growth.
The direct-to-consumer genetic testing market is segmented as follows:
The direct-to-consumer genetic testing market has been analyzed and segmented on the basis of test type, technology, distribution channel, and geography. Based on technology, the market is segmented into whole genome sequencing, single nucleotide polymorphism chips, targeted analysis, and others. The single nucleotide polymorphism chips segment held the largest market share in 2022 and is estimated to register the highest CAGR during 2022–2030. Whole genome sequencing is increasingly used in clinical settings to diagnose rare genetic diseases, guide cancer treatment decisions, and predict disease risk. As per the study "Genome sequencing is highly effective at diagnosing genetic disorders in newborns and infants," published by The Journal of the American Medical Association (2023), whole genome sequencing (WGS) is nearly twice as effective as targeted gene sequencing test at identifying abnormalities responsible for genetic disorders in newborns and infants. The higher acceptance of sequencing procedures in the field of genomics is anticipated to fuel the market growth for the segment during 2022–2030.
Based on test type, the market is segmented into ancestry testing, nutrigenomics testing, predictive testing, carrier testing, and others. The ancestry testing segment held the largest market share in 2022, whereas the predictive testing segment is projected to register the highest CAGR during 2022–2030.
Based on distribution channel, the direct-to-consumer genetic testing market is segmented into online and offline. The online segment held a larger share of the market in 2022 and is anticipated to register a higher CAGR in the market during 2022–2030.
Region Analysis – Direct-to-Consumer Genetic Testing Market
In terms of geography, the global direct-to-consumer genetic testing market is segmented into North America, Europe, Asia Pacific, the Middle East & Africa, and South & Central America. North America held the largest market share during 2022–2030. Asia Pacific is the fastest-growing region for the market. The proliferation of the direct-to-consumer genetic testing market in Asia Pacific is attributed to the increasing need for superior treatment solutions, rising awareness of the early screening of genetic disorders, and growing focus on research and development activities. Additionally, a surge in the R&D for genomics, a large pool of patients, and upgrades in healthcare infrastructure are projected to favor the growth of the direct-to-consumer genetic testing market in Asia Pacific during 2022–2030.
Genesis Healthcare Co; Ancestry Genomics Inc; Color Health Inc; Helix Inc; Myriad Genetics, Inc; Living DNA Ltd; 7andMe Inc; Genetic Technologies Ltd; Gene By Gene Ltd; and Full Genomes Corp Inc. are among the leading companies operating in the direct-to-consumer genetic testing market.
Contact Us
Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com